What TMC Group does

TMC Group is a privately held Canadian specialty manufacturer founded in 2004 and headquartered in North Vancouver, British Columbia. The company manufactures high-purity enriched stable isotopes — currently Ytterbium-176, Gallium-69, Gadolinium-160, and Palladium-104 — that serve as the starting materials for medical radioisotopes used in targeted cancer therapies (notably Lutetium-177 and the emerging Terbium-161) and diagnostic imaging. Production is performed at a 30,000+ square-foot integrated facility using proprietary isotope-manufacturing technologies, custom in-house equipment, and specialized production processes, achieving demonstrated isotopic purity of up to 99.9%. Cumulative shipments exceed 13 kg since 2004, with 2025 output of over 2 kg of Yb-176 at 99.7%+ purity and a near-1 kg Ga-69 run in 2026. The company emphasizes its Western, geopolitically stable supply base as a differentiated alternative to incumbent producers concentrated in volatile regions.

Name

TMC Group

Legal name

TMC Group

Website

https://tmc-group.ca

Company type

Private

Founded year

2004

Operating status

Operating

Headcount range

11–50 employees

Short description

TMC Group is a Canadian manufacturer of high-purity enriched stable isotopes (Yb-176, Ga-69, Gd-160, Pd-104) used as starting materials for medical radioisotopes in cancer therapy and diagnostics, selling globally to radiopharmaceutical companies, biotech firms, and research institutions.

Ownership category

akta.pro rank

Product category

Stable Isotope Manufacturing

NAICS

Ground or Treated Mineral and Earth Manufacturing (327992), Chemical Manufacturing (325)

SIC

Miscellaneous Chemical Products (2890)

akta.pro primary industry

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)

akta.pro secondary industry

Nuclear Medicine Imaging Tracers & PET/SPECT Supply Chain (FDG, Ga-68, logistics/cold chain) (EUAKAIAE)

Keywords

• Stable isotope manufacturing
• Enriched isotope production
• Medical radioisotope supply
• Ytterbium-176 production
• Isotope enrichment technology

Headquarters

HQ city

North Vancouver

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure

Revenue model

1. High-Purity Stable Isotope Sales: One-time product sales of manufactured stable isotopes including Ytterbium-176, Gallium-69, and Gadolinium-160. Sold in various quantities from small research-scale batches to large commercial volumes. Customers include radiopharmaceutical companies, biotech firms, research institutions, and isotope distributors worldwide.
2. Custom Isotope Manufacturing: Bespoke manufacturing services adapting proprietary technologies and processes to produce specialized stable isotopes as required by customers. Flexibility to adjust production based on specific customer demands.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

TMC Group manufactures high-purity enriched stable isotopes, including Ytterbium-176, Gallium-69, Gadolinium-160, and Palladium-104, for use in medical radioisotope production and scientific research. The company operates a specialty manufacturing facility in North Vancouver, British Columbia, and ships its isotope products to customers worldwide.

Product overview

TMC Group is a manufacturer of high-purity enriched stable isotopes that offers a portfolio of non-radioactive isotopes including Ytterbium-176, Gallium-69, Gadolinium-160, and Palladium-104. The company's products are manufactured using proprietary isotope-manufacturing technologies, custom equipment designed in-house, and specialized production processes. TMC Group's stable isotopes serve as essential starting materials for creating medical radioisotopes used in targeted cancer treatments and diagnostic applications. The company produces isotopes at demonstrated isotopic purity reaching up to 99.9%, with production capabilities ranging from small research-scale batches to large commercial volumes. The company operates a 30,000+ square-foot isotope production facility in North Vancouver, Canada.

Differentiator

Problem solved

Functional benefit

Products and services

• Ytterbium-176 (Yb-176)
• Gallium-69 (Ga-69)
• Gadolinium-160 (Gd-160)
• Palladium-104 (Pd-104)

Quantifiable outcome

• 99.9% isotopic purity achieved
• +4 more outcomes

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Canadian Nuclear Isotope Council (CNIC)Others · 7 August 2025TMC Group joined CNIC to be part of a growing national effort to strengthen Canada's isotope supply chain. CNIC has over 110 members from across Canada's isotope supply chain. TMC Group will participate in federal and provincial advocacy opportunities, in-person and virtual events, and educational programming. CNIC's goal is to double Canadian isotope production by 2030 as outlined in the Isotopes for Hope campaign.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• SHINE Technologies: Emerging medical isotope producer using fusion-based neutron generation. Competes with established supply for Mo-99/Lu-177 and represents a next-generation alternative to traditional reactor-based production.

Direct peers

• Cambridge Isotope Laboratories: Largest commercial manufacturer of enriched stable isotopes for research, medical, and industrial applications. Most directly comparable to TMC as a pure-play stable isotope producer with global customers in pharma and life sciences.
• Isoflex: Producer of stable isotopes and isotope-labeled compounds for research, diagnostics, and pharmaceuticals. Comparable to TMC as a specialty isotope manufacturer serving similar end markets.
• Trace Sciences International: Canadian-based manufacturer of enriched stable isotopes serving research, industrial, and medical applications. Directly comparable in scale and product mix to TMC.

Broad incumbents

• URENCO: European uranium enrichment company with stable isotope production capabilities. Operates at far larger scale than TMC in the broader isotope value chain.
• BWXT Medical: Diversified nuclear technology company with a medical isotope and radiopharmaceutical manufacturing segment. Larger-scale competitor in the medical isotope supply chain.
• Nordion: Canadian-based medical isotope supplier producing radioisotopes including Mo-99. Shares TMC's Canadian heritage and radiopharma customer base, though downstream in the value chain.
• Sigma-Aldrich (Merck KGaA): Global life science and specialty chemicals supplier offering a broad catalog of stable isotopes alongside a much wider chemicals and reagents portfolio. Competes with TMC in research-grade isotope supply.
• Curium: Global nuclear medicine company producing radiopharmaceuticals and medical isotopes for diagnostic imaging. Downstream competitor in the radiopharma value chain feeding similar end customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/tmc-group-canada

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TMC Group